FDA approves Revolution Medicines’ pancreatic cancer drug Rasonque, but patients face delayed access

The U.S. Food and Drug Administration has granted approval to Rasonque, a new therapy for pancreatic cancer developed by Revolution Medicines. The decision follows clinical data that showed the drug nearly doubled median overall survival for patients with the disease.

The approval was welcomed by researchers and patient‑advocacy groups as a significant advance against a cancer type with few effective treatments. However, the excitement is tempered by practical challenges in getting the drug to patients.

Revolution Medicines had operated an expanded‑access program that allowed patients to receive Rasonque before formal approval. That program was closed once the FDA cleared the drug, leaving patients who were already in the pipeline without a clear path to obtain the medication.

The situation underscores the need for smoother mechanisms to transition promising therapies from trial or compassionate‑use settings to broader market availability, especially for high‑need cancers like pancreatic cancer.